FdaApplication
BLA 125084
Identifiers
- fda_app_no: BLA125084
Properties
| Property | Value |
|---|---|
| applicant_name | ImClone LLC a wholly-owned subsidiary of Eli Lilly and Company |
| application_type | BLA |
| approval_date | 2004-02-12 |
Revenue by product
ERBITUX
| Period | Revenue |
|---|---|
| Q4 2024 | $175.0M |
| Q3 2024 | $152.0M |
| Q2 2024 | $155.8M |
| Q1 2024 | $144.6M |
| Q4 2023 | $150.2M |
| Q3 2023 | $153.9M |
| Q2 2023 | $162.5M |
| Q1 2023 | $129.9M |
| Q4 2022 | $158.2M |
| Q3 2022 | $144.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
ERBITUX
| Period | Revenue |
|---|---|
| Q4 2024 | $175.0M |
| Q3 2024 | $152.0M |
| Q2 2024 | $155.8M |
| Q1 2024 | $144.6M |
| Q4 2023 | $150.2M |
| Q3 2023 | $153.9M |
| Q2 2023 | $162.5M |
| Q1 2023 | $129.9M |
| Q4 2022 | $158.2M |
| Q3 2022 | $144.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ERBITUX | CETUXIMAB | 100MG/50ML (2MG/ML) | VIAL;INTRAVENOUS |
| ERBITUX | — | 200MG/100ML (2MG/ML) | Injection |
2 products